

# Alona Muzikansky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1237928/publications.pdf>

Version: 2024-02-01

123  
papers

4,185  
citations

159525

30  
h-index

123376

61  
g-index

125  
all docs

125  
docs citations

125  
times ranked

7196  
citing authors

#	ARTICLE	IF	CITATIONS
1	A pilot mixedâ€methods randomized controlled trial of verbal versus electronic screening for adverse social determinants of health. <i>Journal of the American College of Emergency Physicians Open</i> , 2022, 3, e12678.	0.4	5
2	Fluorescence Polarization Imaging of Methylene Blue Facilitates Quantitative Detection of Thyroid Cancer in Single Cells. <i>Cancers</i> , 2022, 14, 1339.	1.7	4
3	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	0
4	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinaseâ€Positive Lung Cancer and CNS-Specific Relapse. <i>JCO Precision Oncology</i> , 2022, 6, e2100522.	1.5	8
5	Clinicopathologic characteristics and outcomes for patients with <i>KRAS</i> G12D-mutant non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21024-e21024.	0.8	0
6	Cost-effectiveness of Implementing Smoking Cessation Interventions for Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e2216362.	2.8	9
7	Complete evaluation of resistance mechanisms to first-line osimertinib requires tissue biopsy.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21154-e21154.	0.8	1
8	Phase 2 trial of bavituximab with chemoradiation and adjuvant temozolomide in newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2030-2030.	0.8	3
9	Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1048-1057.	3.2	129
10	Temperature induced changes in the optical properties of skin in vivo. <i>Scientific Reports</i> , 2021, 11, 754.	1.6	13
11	Clinical factors associated with massive pulmonary embolism and PE-related adverse clinical events. <i>International Journal of Cardiology</i> , 2021, 330, 194-199.	0.8	3
12	Isolation of intact extracellular vesicles from cryopreserved samples. <i>PLoS ONE</i> , 2021, 16, e0251290.	1.1	7
13	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2024-2024.	0.8	4
14	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	0.5	35
15	Validating Techniques for Measurement of Cutaneous Neurofibromas. <i>Neurology</i> , 2021, 97, S32-S41.	1.5	6
16	Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. <i>Neurology</i> , 2021, 97, S99-S110.	1.5	2
17	Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	21
18	Examining the effects of stress and psychological distress on smoking abstinence in cancer patients. <i>Preventive Medicine Reports</i> , 2021, 23, 101402.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). <i>Clinical Cancer Research</i> , 2021, 27, 1604-1611.	3.2	18
20	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERTIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	0.6	0
21	Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1406.	3.8	61
22	Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 815-827.	1.1	12
23	Comparison of 4 Acute Pulmonary Embolism Mortality Risk Scores in Patients Evaluated by Pulmonary Embolism Response Teams. <i>JAMA Network Open</i> , 2020, 3, e2010779.	2.8	26
24	NIMG-07. LONG-TERM FOLLOW-UP OF SCHWANNOMA GROWTH BEHAVIOR IN ADULT NEUROFIBROMATOSIS TYPE 2 AND SCHWANNOMATOSIS PATIENTS USING WHOLE-BODY MRI. <i>Neuro-Oncology</i> , 2020, 22, ii148-ii148.	0.6	0
25	Eosinophil and lymphocyte counts predict bevacizumab response and survival in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa031.	0.4	8
26	Cell release during perfusion reflects cold ischemic injury in rat livers. <i>Scientific Reports</i> , 2020, 10, 1102.	1.6	11
27	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii11-ii11.	0.6	1
28	High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience. <i>Journal of Clinical Oncology</i> , 2020, 38, 9586-9586.	0.8	14
29	A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 9595-9595.	0.8	5
30	Randomized Trial of a Smartphone Mobile App to Improve Symptoms and Adherence to Oral Therapy for Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 133-141.	2.3	42
31	CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB. <i>Neuro-Oncology</i> , 2020, 22, ii53-ii53.	0.6	1
32	NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii138-ii139.	0.6	0
33	CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2020, 22, ii40-ii40.	0.6	0
34	Septal bowing and pulmonary artery diameter on computed tomography pulmonary angiography are associated with short-term outcomes in patients with acute pulmonary embolism. <i>Emergency Radiology</i> , 2019, 26, 623-630.	1.0	21
35	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 5799-5807.	3.2	166
36	Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3446-3454.	0.8	73

#	ARTICLE	IF	CITATIONS
37	Early molecular oxidative stress biomarkers of ischemic penumbra in acute stroke. <i>Neurology</i> , 2019, 93, e1288-e1298.	1.5	36
38	Fluorescence Polarization of Methylene Blue as a Quantitative Marker of Breast Cancer at the Cellular Level. <i>Scientific Reports</i> , 2019, 9, 940.	1.6	36
39	Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. <i>Histopathology</i> , 2019, 75, 649-659.	1.6	25
40	Computed Tomography Imaging Characteristics of Non-EGFR-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 339-349.	1.1	24
41	Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. <i>Neuro-Oncology</i> , 2019, 21, 854-866.	0.6	18
42	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	0.8	159
43	EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	0.8	286
44	ACTR-61. A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi27-vi27.	0.6	4
45	Randomized Trial of a Tailored Cognitive-Behavioral Therapy Mobile Application for Anxiety in Patients with Incurable Cancer. <i>Oncologist</i> , 2019, 24, 1111-1120.	1.9	61
46	Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 547-552.	0.5	57
47	Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2619-2619.	0.8	3
48	Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8507-8507.	0.8	2
49	Multimodal quantitative imaging of brain cancer in cultured cells. <i>Biomedical Optics Express</i> , 2019, 10, 4237.	1.5	6
50	Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. <i>Annals of Neurology</i> , 2018, 83, 980-993.	2.8	110
51	Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. <i>Cancer</i> , 2018, 124, 1438-1448.	2.0	38
52	ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	0.6	1
53	NCMP-22. TREATMENT-RELATED ADVERSE EFFECTS IN PATIENTS WITH MALIGNANT GLIOMA: ESTABLISHMENT OF KEY FEATURES FOR PSEUDOPROGRESSION AND TREATMENT-INDUCED NECROSIS.. <i>Neuro-Oncology</i> , 2018, 20, vi198-vi198.	0.6	1
54	HOUT-15. CIRCULATING BLOOD CELL COUNTS AS POTENTIAL BIOMARKERS OF OUTCOMES IN RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, vi116-vi116.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 4643-4649.	3.2	37
56	Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2032-2032.	0.8	2
57	The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8544-8544.	0.8	8
58	Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 8573-8573.	0.8	1
59	Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21231-e21231.	0.8	6
60	Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms. <i>PLoS ONE</i> , 2018, 13, e0191345.	1.1	11
61	An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1123-1128.	3.3	133
62	Effects of Early Integrated Palliative Care on Caregivers of Patients with Lung and Gastrointestinal Cancer: A Randomized Clinical Trial. <i>Oncologist</i> , 2017, 22, 1528-1534.	1.9	139
63	Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 458-466.	0.5	120
64	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 131, 603-610.	1.4	69
65	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	1.5	6
66	Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 834-841.	0.8	603
67	Randomized trial of a cognitive-behavioral therapy mobile app for anxiety in patients with incurable cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10022-10022.	0.8	2
68	Improved coping to mediate the positive effects of integrated palliative care on quality of life and depression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10023-10023.	0.8	1
69	Randomized trial of a smartphone mobile app for adherence to oral chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10055-10055.	0.8	5
70	Phase 1 study of onalespib, HSP90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS2617-TPS2617.	0.8	1
71	Randomized trial of a cognitive-behavioral therapy mobile app for anxiety in patients with incurable cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 175-175.	0.8	5
72	The positive effects of early integrated palliative care on patient coping strategies, quality of life, and depression.. <i>Journal of Clinical Oncology</i> , 2017, 35, 92-92.	0.8	6

#	ARTICLE	IF	CITATIONS
73	Multifocal adenocarcinoma of the lung: Factors predictive for local therapy.. Journal of Clinical Oncology, 2017, 35, e20041-e20041.	0.8	1
74	Randomized trial of a smartphone mobile app for adherence to oral chemotherapy.. Journal of Clinical Oncology, 2017, 35, 230-230.	0.8	1
75	Cost Analysis of a Randomized Trial of Early Palliative Care in Patients with Metastatic Nonsmall-Cell Lung Cancer. Journal of Palliative Medicine, 2016, 19, 842-848.	0.6	62
76	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology, 2016, 18, 849-854.	0.6	45
77	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. Journal of Neuropathology and Experimental Neurology, 2016, 75, 516-526.	0.9	67
78	End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. Journal of Palliative Medicine, 2016, 19, 1316-1319.	0.6	7
79	Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial. Contemporary Clinical Trials, 2016, 50, 54-65.	0.8	22
80	Identification of the novel activity-driven interaction between synaptotagmin 1 and presenilin 1 links calcium, synapse, and amyloid beta. BMC Biology, 2016, 14, 25.	1.7	33
81	Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2â€“Associated Vestibular Schwannomas. Journal of Clinical Oncology, 2016, 34, 1669-1675.	0.8	92
82	Retinal Dystrophy and Optic Nerve Pathology in the Mouse Model of Mucopolidosis IV. American Journal of Pathology, 2016, 186, 199-209.	1.9	22
83	Randomized trial of early integrated palliative and oncology care.. Journal of Clinical Oncology, 2016, 34, 10003-10003.	0.8	8
84	Early integrated palliative care to improve family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer.. Journal of Clinical Oncology, 2016, 34, 10131-10131.	0.8	2
85	A phase I study of MLN0128 and bevacizumab in patients with recurrent glioblastoma and other solid tumors.. Journal of Clinical Oncology, 2016, 34, 2013-2013.	0.8	2
86	Rociletinib-associated cataracts in EGFR-mutant NSCLC.. Journal of Clinical Oncology, 2016, 34, 9042-9042.	0.8	1
87	The challenges of repeat biopsies at acquired resistance to EGFR TKIs.. Journal of Clinical Oncology, 2016, 34, e20571-e20571.	0.8	1
88	Randomized trial of early integrated palliative and oncology care.. Journal of Clinical Oncology, 2016, 34, 104-104.	0.8	6
89	Effect of early integrated palliative care on family caregivers (FC) outcomes for patients with gastrointestinal and lung cancer.. Journal of Clinical Oncology, 2016, 34, 234-234.	0.8	5
90	Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from nonâ€“small cell lung cancer. Cancer, 2015, 121, 4165-4172.	2.0	15

#	ARTICLE	IF	CITATIONS
91	Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. JAMA Surgery, 2015, 150, 465.	2.2	9
92	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro-Oncology, 2015, 17, 862-867.	0.6	111
93	Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertility and Sterility, 2015, 103, 761-768.e1.	0.5	23
94	Heterogeneity Underlies the Emergence of <i>EGFR</i> T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. Cancer Discovery, 2015, 5, 713-722.	7.7	429
95	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clinical Cancer Research, 2015, 21, 3610-3618.	3.2	79
96	Outcome of patients with de novo versus nevus-associated melanoma. Journal of the American Academy of Dermatology, 2015, 72, 54-58.	0.6	71
97	Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.. Journal of Clinical Oncology, 2015, 33, 2025-2025.	0.8	1
98	Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.. Journal of Clinical Oncology, 2015, 33, 8015-8015.	0.8	10
99	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2015, 33, TPS2080-TPS2080.	0.8	1
100	Clinical implementation of anchored multiplex PCR with targeted next-generation sequencing for detection of ALK, ROS1, RET and NTRK1 fusions in non-small cell lung carcinoma.. Journal of Clinical Oncology, 2015, 33, 8095-8095.	0.8	1
101	AT-37PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA. Neuro-Oncology, 2014, 16, v16-v17.	0.6	0
102	Postoperative Intensive Care Unit Requirements After Elective Craniotomy. World Neurosurgery, 2014, 81, 165-172.	0.7	73
103	Outcomes and patterns of care in adult skull base chondrosarcomas from the SEER database. Journal of Clinical Neuroscience, 2014, 21, 1497-1502.	0.8	21
104	Perceptions of Health Status and Survival in Patients With Metastatic Lung Cancer. Journal of Pain and Symptom Management, 2014, 48, 548-557.	0.6	48
105	Outcomes and patterns of care in adult skull base chordomas from the Surveillance, Epidemiology, and End Results (SEER) database. Journal of Clinical Neuroscience, 2014, 21, 1490-1496.	0.8	76
106	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. Neuro-Oncology, 2014, 16, v16-v16.	0.6	0
107	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy.. Journal of Clinical Oncology, 2014, 32, 2004-2004.	0.8	4
108	Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.. Journal of Clinical Oncology, 2014, 32, 2020-2020.	0.8	1



#	ARTICLE	IF	CITATIONS
109	Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma.. Journal of Clinical Oncology, 2014, 32, 2031-2031.	0.8	2
110	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results.. Journal of Clinical Oncology, 2014, 32, 2053-2053.	0.8	1
111	SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.. Journal of Clinical Oncology, 2014, 32, 7514-7514.	0.8	35
112	A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8088-8088.	0.8	4
113	Cost analysis of a randomized trial of early palliative care (PC) in patients with metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 4-4.	0.8	1
114	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.. Journal of Clinical Oncology, 2014, 32, 2027-2027.	0.8	0
115	Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2013-2013.	0.8	16
116	Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas.. Journal of Clinical Oncology, 2013, 31, TPS2104-TPS2104.	0.8	2
117	Reply to I.B. Tan et al. Journal of Clinical Oncology, 2012, 30, 2164-2164.	0.8	0
118	The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2012, 30, 7010-7010.	0.8	12
119	Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).. Journal of Clinical Oncology, 2012, 30, 7524-7524.	0.8	9
120	Relationship between whole-body tumor burden and quality of life in patients with neurofibromatosis.. Journal of Clinical Oncology, 2012, 30, 6136-6136.	0.8	0
121	Multimodal optical imaging and spectroscopy for the intraoperative mapping of nonmelanoma skin cancer. Journal of Applied Physics, 2009, 105, 102010.	1.1	13
122	Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. American Journal of Clinical Pathology, 2007, 127, 642-650.	0.4	1
123	Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.. Blood, 2005, 106, 3290-3290.	0.6	0